B&C Biopharm (Here at B&C Biopharm, we are searching for global partnership to share and distribute our innovative health technology and products. Since 1999, we have studied and developed technology, applying bio-transformation in functional Ginsenosides of Platycodon root extract.the exclusive right {C}2.The treatment of fatty liver disease3.Safety: three phases of preclinical trials and many number of participants for clinical tests of Dr. J confirm its safety. Due to the fact that Dr. J has been developed as a pharmaceutical drug, bio-transformed Ginsenosides completed three phases of preclinical trials, which the FDA does not require for the approval of health functional food but for medicines. Clinical trials of Dr. J was practiced with 100 subjects although required numbers of participants are 40. For instance, clinical studies for the safety of genus hovenia was practiced with 40 participants. Moreover, active components of Dr. J were identified to have inhibitory activity on HCV replication enzyme (RNA polymerase, NS5B). Through clinical studies, we also notified the inhibitory activity of Dr. J with HCV infected cell line. According to Donguibogam (Principles and Practice of Eastern Medicine) and (Chinese botanical lists), Platycodon root has been well-known with its excellent efficacy in the treatment of diverse diseases for thousand years. The verified efficacy of Dr. J through appropriate clinical studies proved effectiveness of Platycodon root extract for liver disease. We have reliable documents such asthe KFDA Approval and patents of our innovative technology. The global pharmaceutical market for liver disease is about $12 billion (2010). With capability of mass production, we are prepared to distribute Dr. J through global partnerships.